Last A$0.17 AUD
Change Today +0.005 / 3.03%
Volume 13.8K
As of 6:04 PM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

idt australia ltd (IDT) Snapshot

Open
A$0.17
Previous Close
A$0.17
Day High
A$0.17
Day Low
A$0.17
52 Week High
01/15/14 - A$0.45
52 Week Low
11/10/14 - A$0.17
Market Cap
13.2M
Average Volume 10 Days
41.7K
EPS TTM
A$-0.10
Shares Outstanding
77.7M
EX-Date
10/5/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IDT AUSTRALIA LTD (IDT)

Related News

No related news articles were found.

idt australia ltd (IDT) Related Businessweek News

No Related Businessweek News Found

idt australia ltd (IDT) Details

IDT Australia Limited provides products, research and development, and other technical services for the pharmaceutical and allied industries in Australia. It is involved in the development, scale-up, and manufacture of high potency and cytotoxic API, and finished drug products. The company develops cytotoxics, anti-cancer drugs, anti-psychotics, antibiotics, beta lactams, and controlled drugs. It also offers various specialist formulation development manufacturing, packaging, and dispensing services; and clinical trials research and pharmacy services in a range of therapeutic areas. In addition, the company manufactures active and placebo clinical trial supplies in various dosage forms, such as tablets, coated tablets, capsules, suspensions, liquids, sprays, patches, lyophilised powders, and ointments. Further, it offers analytical services, such as method validation/verification, compendial testing, stability testing, microbiology testing, cleaning validation, identity testing, assay, related substances, residual solvents, limit testing, melting point, clarity, gravimetric, viscosity, dissolution, uniformity of dosage, hardness/friability/disintegration, and chemical monitoring. IDT Australia Limited is headquartered in Boronia, Australia.

idt australia ltd (IDT) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$301.0K
Founder, Director and Member of Nomination & ...
Total Annual Compensation: A$27.5K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$57.0K
Vice President of Legal & Corporate Developme...
Total Annual Compensation: A$196.0K
Vice President of Clinical Services and Gener...
Total Annual Compensation: A$180.6K
Compensation as of Fiscal Year 2014.

idt australia ltd (IDT) Key Developments

IDT Australia Limited Presents at 5th Annual Australian Microcap Investment Conference, Oct-22-2014 04:15 PM

IDT Australia Limited Presents at 5th Annual Australian Microcap Investment Conference, Oct-22-2014 04:15 PM. Venue: Sofitel Molbourne On collins, Arthur Streeton Auditorium, 25 Collins Street, Melbourne, VIC 3000, Australia. Speakers: Paul Donald Richard MacLeman, Chief Executive Officer, Managing Director and Director.

IDT Australia Limited Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended July 31, 2014

IDT Australia Limited announced consolidated earnings results for the fourth quarter and full year ended July 31, 2014. For the quarter, the company reported revenue increased to $420.7 million from $412.1 million, the 17th year over year quarterly increase in the last 18 quarters. Adjusted EBITDA increased to $10.4 million from $9.7 million, the tenth consecutive year-over-year quarterly increase. Income from operations increased to $5.8 million from $1.4 million. Net income attributable to IDT increased to $7.7 million, including a net benefit from income taxes of $4.1 million, from a net loss of $3.7 million in the fourth quarter of 2013. Due to the recent and expected future profitability of one of IDT’s foreign subsidiaries, IDT fully reversed the valuation allowance that had been applied against this subsidiary’s deferred income tax assets. Diluted EPS increased to $0.33 from a diluted loss per share of $0.17. Non-GAAP diluted EPS increased to $0.39 from $0.13. Net cash provided by operating activities in the fourth quarter of 2014 increased to $16.1 million from $12.1 million. For the full year 2014, the company reported revenue increased to $1,651.5 million from $1,620.6 million. Adjusted EBITDA increased to $45.3 million from $39.4 million. Income from operations increased to $29.8 million from $29.4 million. Net income attributable to IDT increased to $18.8 million from $11.6 million. Diluted EPS increased to $0.82 from $0.52. Non-GAAP diluted EPS increased to $1.41 from $1.09. Net cash provided by operating activities was $45.7 million compared to $57.2 million. Capital expenditures in the corresponding full year periods were $17.0 million compared to $14.5 million.

IDT Australia Limited, Annual General Meeting, Oct 23, 2014

IDT Australia Limited, Annual General Meeting, Oct 23, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDT:AU A$0.17 AUD +0.005

IDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDT.
View Industry Companies
 

Industry Analysis

IDT

Industry Average

Valuation IDT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDT AUSTRALIA LTD, please visit www.idtaus.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.